February 2, 2026- Medtronic announced three significant U.S. milestones that expand access, choice, and flexibility for people living with type 1 and insulin‑requiring type 2 diabetes. These milestones include Medicare access for the MiniMed™ 780G system paired with the Instinct sensor, made by Abbott, FDA clearance for the system’s use with ultra rapid‑acting insulins, and clearance of the MiniMed™ 780G system for use with the Instinct sensor for insulin-requiring type 2 diabetes.